Many Americans have been resorting to this to heal ASD in their child. The brand-new U.S clinical trial is said to be the very first to get U.S. Food and Drug Administration’s approval. Administered and managed by Dr. Michael Chez, the Director of Paediatric Neurology, Sutter Medical Center, a team of researchers sometime back had published the outcome of a Phase II Clinical Trial that looked into the effectiveness and security of autologous umbilical cord blood cells for autistic children that deployed a placebo-managed, double-blind design. Back in 2017, these medical researchers at Duke University also published a Phase I security trial assessing autologous umbilical cord blood in autistic children. The emphasis on cord blood cells being a potential cellular therapy accompanied with favourable findings from past clinical studies, promises a brighter future in treating ASD. CBR in its initiative to explore the potential of stem cells has offered institutional funding for Stutter clinical researchers.
The Scope of Newborn Stem Cells
The emphasis on cord blood cells being effective in treating ASD stems from its innate benefits. Cells from umbilical cord blood have set of benefits such as:
· Anti-inflammatory properties – Research has revealed that stem cells possess the capacity to normalize inflammation and migrate to the location of neurologic injury.
· Secure and available – Blood from the umbilical cord is collected easily when a baby is born and can be stored indefinitely for any future use by a close family member or the newborn donor
· Bystander effect- It is said that infused stem cells secrete factors which regenerates the body’s innate healing mechanism in and around a surrounding tissue through paracrine signalling, which is also called the bystander effect.
ASD Research Kickstarts
The very first clinical research making use of the blood from umbilical cord that was earlier banked from the autistic child was completed recently. The children between the age group 2 and 6 who had ASD were researched on for this study. The objective of this trial was to evaluate if blood from the umbilical cord was a secure means to use it on these children and record any health improvement that might occur in a year. This children team was given one dose of stem cells via intravenous infusion and the effects were observed. This study paved the foundation for other advanced studies to commence in future. It proved that cord blood cell was a secure therapy mode when transferred as an infusion. It also recognized certain symptoms that could have been influenced.